Search Results

You are looking at 111 - 120 of 290 items for :

  • "neutropenia" x
Clear All
Full access

William J. Gradishar, Benjamin O. Anderson, Ron Balassanian, Sarah L. Blair, Harold J. Burstein, Amy Cyr, Anthony D. Elias, William B. Farrar, Andres Forero, Sharon Hermes Giordano, Matthew Goetz, Lori J. Goldstein, Clifford A. Hudis, Steven J. Isakoff, P. Kelly Marcom, Ingrid A. Mayer, Beryl McCormick, Meena Moran, Sameer A. Patel, Lori J. Pierce, Elizabeth C. Reed, Kilian E. Salerno, Lee S. Schwartzberg, Karen Lisa Smith, Mary Lou Smith, Hatem Soliman, George Somlo, Melinda Telli, John H. Ward, Dottie A. Shead and Rashmi Kumar

letrozole alone group included neutropenia (54% vs 1%) and leukopenia (19% vs 0%). Based on this study, the FDA approved palbociclib in combination with letrozole for the treatment of postmenopausal women with ER-positive, HER2-negative advanced breast

Full access

Ranjana H. Advani

associated with a 5% improvement in modified PFS but also higher rates of febrile neutropenia and neuropathy. The FDA indication approval recommends growth factor support with BV‐AVD. 8 The other issue to consider with these regimens is cost. Because of the

Full access

Melinda Telli

treated with docetaxel had significantly higher rates of febrile neutropenia and neuropathy, whereas in patients treated with carboplatin, vomiting appeared to be somewhat more common,” explained Dr. Telli. Furthermore, she said, “disappointingly, there

Full access

Ingrid A. Mayer

. Mayer suggested. It is worth noting that, because of its side effect profile (neutropenia, gastrointestinal toxicity), palbociclib may not be the best choice for all patients. Finally, targeting methylation through inhibition of histone deacetylase

Full access

Steven M. Horwitz, Andrew D. Zelenetz, Leo I. Gordon, William G. Wierda, Jeremy S. Abramson, Ranjana H. Advani, C. Babis Andreadis, Nancy Bartlett, John C. Byrd, Luis E. Fayad, Richard I. Fisher, Martha J. Glenn, Thomas M. Habermann, Nancy Lee Harris, Francisco Hernandez-Ilizaliturri, Richard T. Hoppe, Mark S. Kaminski, Christopher R. Kelsey, Youn H. Kim, Susan Krivacic, Ann S. LaCasce, Matthew Lunning, Auayporn Nademanee, Oliver Press, Rachel Rabinovitch, Nishitha Reddy, Erin Reid, Kenneth Roberts, Ayman A. Saad, Lubomir Sokol, Lode J. Swinnen, Julie M. Vose, Joachim Yahalom, Nadeem Zafar, Mary Dwyer, Hema Sundar and Pierluigi Porcu

common grade 3/4 adverse events included thrombocytopenia (32%), neutropenia (22%), anemia (18%), and mucositis (22%). In September 2009, pralatrexate became the first FDA-approved single agent for the treatment of patients with relapsed or refractory

Full access

Harrys A. Torres, Lillian R. Roach, Parag Mahale, Minas P. Economides, Boris Blechacz, Ethan Miller, Roy Borchardt, Anis Rashid, Thein H. Oo, Bhavarth Shukla, Malik Farida, Charles D. Ericsson, Bruno P. Granwehr and Issam I. Raad

. These patients often have immunosuppression due to systemic chemotherapies and underlying hematologic abnormalities, such as neutropenia, anemia, and thrombocytopenia. Before 2013, antiviral therapy for HCV infections consisted of pegylated interferon

Full access

John C. Byrd

III trial of the German CLL Study Group comparing fludarabine and cyclophosphamide to FC plus rituximab for previously untreated patients with chronic lymphocytic leukemia: results on survival, progression-free survival, delayed neutropenias and

Full access

Shira Dinner and Ranjana Advani

well tolerated, and grade 3 or higher adverse events included neutropenia (20%), thrombocytopenia (8%), anemia (6%), and peripheral sensory neuropathy (8%). This agent was approved by the FDA in 2011 for patients with R/R HL for whom ASCT failed, for

Full access

Benjamin Levy, Ashish Saxena and Bryan J. Schneider

%; P =.9). More grade 3/4 adverse events occurred in the ACE arm, including anemia (27% vs 18%; P =.03), neutropenia (90% vs 57%; P <.005), and infection (73% vs 29%; P <.0005), leading to more days of hospitalization and greater intravenous

Full access

Gregory J. Riely, Jamie E. Chaft, Marc Ladanyi and Mark G. Kris

using another test), treatment with crizotinib is recommended. The available data support the use of crizotinib in any line of therapy. 4 , 5 Moreover, the relatively well-tolerated nature of crizotinib (severe toxicities such as neutropenia are rare